Development and Reproduction (한국발생생물학회지:발생과생식)

The Korean Society of Developmental Biology (한국발생생물학회)
권호 표지
DOI QR코드

DOI QR Code

Metformin Synergistically Potentiates the Antitumor Effects of Imatinib in Colorectal Cancer Cells

  • Lee, Jaeryun (Dept. of Medicine, Jeju National University School of Medicine) ;
  • Park, Deokbae (Dept. of Histology, Jeju National University School of Medicine) ;
  • Lee, Youngki (Dept. of Histology, Jeju National University School of Medicine)
  • Received : 2017.04.12
  • Accepted : 2017.04.18
  • Published : 2017.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Metformin is the most commonly prescribed anti-diabetic drug with relatively minor side effect. Substantial evidence has suggested that metformin is associated with decreased cancer risk and anticancer activity against diverse cancer cells. The tyrosine kinase inhibitor imatinib has shown powerful activity for treatment of chronic myeloid leukemia and also induces growth arrest and apoptosis in colorectal cancer cells. In this study, we tested the combination of imatinib and metformin against HCT15 colorectal cancer cells for effects on cell viability, cell cycle and autophagy. Our data show that metformin synergistically enhances the imatinib cytotoxicity in HCT15 cells as indicated by combination and drug reduction indices. We also demonstrate that the combination causes synergistic down-regulation of pERK, cell cycle arrest in S and $G_2/M$ phases via reduction of cyclin B1 level. Moreover, the combination resulted in autophagy induction as revealed by increased acidic vesicular organelles and cleaved form of LC3-II. Inhibition of autophagic process by chloroquine led to decreased cell viability, suggesting that induction of autophagy seems to play a cell protective role that may act against anticancer effects. In conclusion, our present data suggest that metformin in combination with imatinib might be a promising therapeutic option in colorectal cancer.

Keywords

References

  1. Abdel-Aziz AK, Azab SSE, Youssef SS, El-Sayed AM, El-Demerdash E, Shouman S (2015) Modulation of imatinib cytotoxicity by selenite in HCT116 colorectal cancer cells. Basic Clin Pharmaco Toxicol 116:37-46. https://doi.org/10.1111/bcpt.12281
  2. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD (2009) Metformin inhibits breast cancer cell growth, colony formation and cell cycle arrest in vitro. Cell Cycle 8:909-915. https://doi.org/10.4161/cc.8.6.7933
  3. Attoub S, Rivat C, Rodrigues S, Bocxlaer SV, Bedin M, Bruyneel E, Louvet C, Kornprobst M, Andre' T, Mareel M, Mester J, Gespach C (2002) The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 62:4879-4883.
  4. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Le Marchand-Brustel Y, Bost F (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576-3586. https://doi.org/10.1038/sj.onc.1211024
  5. Chou TC, Talalay P (1981) Generalized equations for the analysis of inhibitions of Michaelis-Menton and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115:207-216.
  6. Crowley LC, O'Donovan TR, Nyhan MJ, JMcKenna SL (2013) Pharmacological agents with inherent anti-auto-phagic activity improve the cytotoxicity of imatinib. Oncol Rep 29:2261-2268. https://doi.org/10.3892/or.2013.2377
  7. De Giorgi U, Verweij J (2005) Imatinib and gastrointestinal stromal tumors: Where do we go from here? Mol Cancer Ther 4:495-501.
  8. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmerman J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566. https://doi.org/10.1038/nm0596-561
  9. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. British Medical Journal 330: 1304-1305. https://doi.org/10.1136/bmj.38415.708634.F7
  10. Genander M, Halford MM, Xu N-J, Eriksson M, Yu Z, Qiu Z, Martling A, Greicius G, Thakar S, Catchpole T, Chumley M, Zdunek S, Wang C, Holm T, Goff SP, Petterson S, Pestell RG, Henkemeyer M, Frisen J (2009) Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression. Cell 139:769-792.
  11. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Muller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22: 1200-1206. https://doi.org/10.1038/leu.2008.84
  12. Huguet F, Giocanti N, Hennequin C, Croisy M, Touboul E, Favaudon V (2008) Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells. Mol Cancer Ther 7:398-406. https://doi.org/10.1158/1535-7163.MCT-07-2023
  13. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic DM, Trajkovic V (2007) Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 64:1290-1302. https://doi.org/10.1007/s00018-007-7080-4
  14. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman SL, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor ST1571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056. https://doi.org/10.1056/NEJM200104053441404
  15. Kundu P, Genander M, Straat K, Classon J, Ridgway RA, Tan EH, Bjork J, Martiling A, van Es J, Sansom OJ, Clevers H, Petterson S, Frisen J (2015) An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth. Sci Transl Med 7(281):281ra44. https://doi.org/10.1126/scitranslmed.3010567
  16. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH (2011) The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 131:752-759.
  17. Li H, Jin X, Zhang Z, Xing Y, Kong X (2013) Inhibition of autophagy enhances apoptosis induced by the PI3K/ AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells. Cell Biochem Funct 31:427-433. https://doi.org/10.1002/cbf.2917
  18. Mendoza MC, Er EE, Blenis J (2011) The RAS-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36:320-327. https://doi.org/10.1016/j.tibs.2011.03.006
  19. Mizushima N, Yoshimori T, Levine B (2010) Methods in mammalian autophagy research. Cell 140:313-326. https://doi.org/10.1016/j.cell.2010.01.028
  20. Nanglia-Makker P, Yu Y, Vasudevan A, Farhara L, Rajendra SG, Levi E, Majumdar AP (2014) Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One 9(1):e84369. https://doi.org/10.1371/journal.pone.0084369
  21. Niehr F, Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Andix B, Ribas A (2011) Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med 9:76-88. https://doi.org/10.1186/1479-5876-9-76
  22. Norbury C, Nurse P (1992) Animal cell cycles and their control. Trends Biochem Sci 19:143-145.
  23. O'Hare T, Deiniger MWN, Eide CA, Clackson T, Druker BJ (2011) Targeting the BCR-ABL signaling pathway in therapy resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 17:212-221. https://doi.org/10.1158/1078-0432.CCR-09-3314
  24. Park D, Lee Y (2014) Biphasic activity of chloroquine in human colorectal cacner cells. Dev Reprod 18:225-231. https://doi.org/10.12717/DR.2014.18.4.225
  25. Popow-Wozniak A, Wozniakowska A, Kaczmarek L, Malicka-Blaszkiewicz M, Nowak D (2011) Apoptotic effect of imatinib on human colon adenocarcinoma cells: Influence on actin cytoskeleton organization and cell migration. Eur J Pharmacol 667:66-73. https://doi.org/10.1016/j.ejphar.2011.05.036
  26. Quinn BJ, Kitagawa H, Memmot RM, Gills JJ, Dennis PA (2013) Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 24(9):469-480. https://doi.org/10.1016/j.tem.2013.05.004
  27. Saglio G, Kim DW, Issaragrisil S, Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259. https://doi.org/10.1056/NEJMoa0912614
  28. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Dpinho RA, Montminy M, Cantley LC (2005) The ki-nase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646. https://doi.org/10.1126/science.1120781
  29. Shi R, Lin J, Gong Y, Yan T, Shi F, Yang X, Liu X, Naren D (2015) The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell. Anti-Cancer Drugs 26(9):913-922. https://doi.org/10.1097/CAD.0000000000000266
  30. Song J, Kang JH, Kang HK, Kim K, Lee S, Choi D, Park D, Lee Y (2011) Mechanism of ethanol-induced Purkinje cell death in developing rat cerebellum: its implication in apoptosis and oxidative damage. Dev Reprod 15:205-213.
  31. Stahtea XN, Roussidis AE, Kanakis I, Tzanakakis GN, Chalkiadakis G, Mavroudis D, Kletsas D, Karmanos NK (2007) Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Int J Cancer 121:2808-2814. https://doi.org/10.1002/ijc.23029
  32. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H (2013) Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. Cell Death Dis 4:e838. https://doi.org/10.1038/cddis.2013.350
  33. Takeuchi H, Kondo Y, Fujiwara K, Kanazawa T, Aoki H, Mills GB, Kondo S (2005) Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65:3336-3346. https://doi.org/10.1158/0008-5472.CAN-04-3640
  34. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, Nakajima N, Nagashima Y, Wada K, Nakagama H, Nakajima A (2008) Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 99:2136-2141. https://doi.org/10.1111/j.1349-7006.2008.00933.x
  35. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Galsauer A, Dufour E, Mutlu GM, Budigner GRS, Chandel N (2014) Metfromin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3:e02242.
  36. Wilcock C, Bailey CJ (1994) Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24:49-57. https://doi.org/10.3109/00498259409043220
  37. Yang ZJ, Chee CE, Huang S, Sinicrope FA (2011) The role of autophagy in cancer: Therapeutic implications. Mol Cancer Ther 10:1533-1541. https://doi.org/10.1158/1535-7163.MCT-11-0047
  38. Zhang J, Yang P, Gary N (2009) Targeting cancer with small molecule kinase inhibitors. Nature Rev Cancer 9:28-39. https://doi.org/10.1038/nrc2559
  39. Zhang Y, Guan M, Zheng Z, Zhang Q, Gao F, Xue Y (2013) Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS One 8(11):e81264. https://doi.org/10.1371/journal.pone.0081264